A PHARMACOPHORE BASED DRUG DESIGN APPROACH TO OVERCOME IMATINIB RESISTANCE AND GET MORE POTENT BCR-ABL TYROSINE KINASE INHIBITOR
AbstractBCR-ABL Tyrosine Kinase inhibitor is an ideal pharmacological target for Chronic Myeloid Leukemia (CML). After the effective use of Imatinib as a therapeutic agent for Chronic Myeloid Leukemia, resistance has been observed in much patience with the treatment of Imatinib. The main objective of this study is to develop some new novel BCR-ABL Tyrosine Kinase inhibitor for the treatment of Chronic Myeloid Leukemia by Structure Activity Relationship (SAR) and Pharmacophore based drug design approach with Imatinib as a prototype drug. Moreover to overcome the resistance with Imatinib and get some new innovative BCR-ABL Tyrosine Kinase inhibitor with increased potency. In this study, we have designed some new BCR-ABL Tyrosine Kinase inhibitor and reported them as potentially new BCR-ABL Tyrosine Kinase inhibitor by using molecular docking analysis and various free internet based Insilco tools. The drug properties like toxicity, metabolic site, Binding energy, Inhibition constant, Ligand efficiency and many other parameters are predicted through In-silico tools.
Article Information
22
1788-1800
1592KB
1357
English
IJPSR
Abhishek Thakur
Department of Pharmaceutical Sciences; Birla Institute of Technology, Mesra, Ranchi -835215, Jharkhand, India
thakurabhishek242@gmail.com
20 November, 2013
20 February, 2014
09 March, 2014
http://dx.doi.org/10.13040/IJPSR.0975-8232.5(5).1788-00
01 May, 2014
Download